Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study
Abstract
Background: Long‐term survivors of non‐Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health‐related quality of life. Little is known about the risk‐to‐benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long‐term fatigue levels was investigated in a cross‐sectional study. Methods: Two self‐administered questionnaires, the 20‐item Multidimensional Fatigue Inventory (MFI‐20) and a Life Situation Questionnaire, were mailed in 2015 to NHL survivors enrolled onto 12 successive clinical studies (1993‐2010) conducted by the Lymphoma Study Association. Private addresses were obtained for 3317 survivors, of whom 1671 (50%) returned the questionnaires. Severe fatigue was defined as MFI‐20 scores ≥60 on dimension scales scored from 0 to 100. Linear regression models were used to assess factors that were linked to increased fatigue levels. Results: The study population included 906 men and 765 women, and the median age was 64 years (age range, 24‐95 years). Overall, 811 survivors had received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)‐like chemotherapy, 518 had received high‐dose CHOP, and 342 had undergone upfront autologous stem cell transplantation; 829 survivors also had received rituximab. In total, 1100 survivors (66%) reported 1 or more late health disorders. Severe fatigue was reported by 602 survivors (37%). Increased fatigue levels were associated ( P < .001) with increased age, obesity, and the presence of health disorders, but not with initial treatment or rituximab. Conclusions: The survey confirms that high proportions long‐term NHL survivors have severe fatigue. The results suggest that initial treatment and the receipt of rituximab have no influence on the development of long‐term fatigue.Keywords
Funding Information
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (AAP-2012-20)
This publication has 22 references indexed in Scilit:
- Cancer-related fatigue—mechanisms, risk factors, and treatmentsNature Reviews Clinical Oncology, 2014
- Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline AdaptationJournal of Clinical Oncology, 2014
- Normative Data of the EORTC QLQ-C30 For the German Population: A Population-Based SurveyPLOS ONE, 2013
- Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control StudyJournal of Clinical Oncology, 2012
- Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELAHaematologica, 2011
- Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trialThe Lancet Oncology, 2009
- Fatigue in Cancer Survivors – Prevalence and CorrelatesOnkologie, 2009
- Quality of life assessment in Hodgkin’s disease: A new comprehensive approachAnnals of Oncology, 1998
- Fatigue in the general norwegian populationJournal of Psychosomatic Research, 1998
- The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigueJournal of Psychosomatic Research, 1995